insurance changes to glp 1 drugs Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss Designing fiscally viable coverage of
Description
Goals get met

GLP-1 receptor agonists have transformed the management of type 2 diabetes and obesity, but their mechanism of delaying gastric emptying presents important clinical considerations

Schedule a consultation with a PEAK clinician

Changes in A1C at 26 weeks were 1.51%, 1.30%, 0.99% and 0.46% for the dulaglutide 1.5 mg, dulaglutide 0.75 mg, exenatide and placebo groups, respectively (both doses of dulaglutide were superior to exenatide

Semaglutide is entering phase 3 evaluation in patients with early AD (NCT04777396)
Sattar, N
